Back to top
more

Axsome Therapeutics (AXSM)

(Delayed Data from NSDQ)

$86.53 USD

86.53
262,197

+0.55 (0.64%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $86.49 -0.04 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Best Momentum Stocks to Buy for July 11th

by Zacks Equity Research

AXSM, HIVE and TIMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 11, 2023.

Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study

by Zacks Equity Research

Axsome (AXSM) doses its first patient in the late-stage, label expansion study of solriamfetol for treating attention deficit hyperactivity disorder.

Axsome (AXSM) Down on Public Offering of Common Stock

by Zacks Equity Research

Axsome (AXSM) is set to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines.

Axsome (AXSM) Soars 8.1%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Axsome (AXSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Why Is Axsome (AXSM) Down 2.5% Since Last Earnings Report?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Axsome (AXSM) Q1 Earnings Beat Estimates, Auvelity Volume Rises

by Zacks Equity Research

Axsome (AXSM) incurs a narrower-than-expected loss in 1Q23. Its revenues beat estimates and stock gains.

Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Axsome (AXSM) delivered earnings and revenue surprises of 80.53% and 252.03%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Axsome (AXSM) Focuses on Auvelity Launch to Fuel Its Growth

by Zacks Equity Research

Axsome's (AXSM) earnings benefit from the launch of Auvelity (AXS-05), meant for treating major depressive disorders.

Intra-Cellular's (ITCI) Caplyta Aids Sales, Overreliance a Woe

by Zacks Equity Research

Intra-Cellular (ITCI) is witnessing growth aided by its sole-marketed drug, Caplyta. However, the lack of other promising candidates in the pipeline is concerning.

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Indrajit Bandyopadhyay headshot

3 Medical Stocks With Solid Growth Potential to Keep Track Of

by Indrajit Bandyopadhyay

Here we discuss three medical stocks - AXSM, MRNA and ISRG - that have the potential to create wealth for investors over the coming years.

Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up

by Zacks Equity Research

Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.

Axsome (AXSM) Down 9.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Axsome (AXSM) Stock Up 17% in Six Months: Here's Why

by Zacks Equity Research

Axsome's (AXSM) shares have surged 17.2% in the past six months, owing to the launch of its first product, Auvelity, in October last year. Also, the addition of Sunosi boosts its top line.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XPH

Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?

by Zacks Equity Research

Sector ETF report for PTH

Jazz's (JAZZ) Q4 Earnings Miss Estimates, New Drugs Drive Sales

by Zacks Equity Research

Jazz (JAZZ) reports dismal fourth-quarter results as earnings and sales miss expectations. Sleep disorder drug Xywav become the company's largest product by net sales during the quarter.

Axsome (AXSM) Q4 Earnings Miss, Auvelity Records First Sales

by Zacks Equity Research

Axsome Therapeutics (AXSM) incurs wider-than-expected loss in Q4 2022. Revenues beat estimates while shares gain.

Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Axsome (AXSM) delivered earnings and revenue surprises of -8.47% and 13.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XPH

Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?

by Zacks Equity Research

Sector ETF report for XPH

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Axsome (AXSM) Rides on New Drug Approval & Sunosi Buyout

by Zacks Equity Research

Axsome (AXSM) receives FDA approval for Auvelity to treat major depressive disorder in August. The Sunosi deal and promising pipeline bode well. Stiff competition in the target market remains a woe.

Indrajit Bandyopadhyay headshot

3 Medical Stocks With Solid Growth Drivers to Keep Track Of

by Indrajit Bandyopadhyay

Here we discuss three medical stocks - AXSM, MRNA and ISRG - that have the potential to create wealth for investors over the coming years.

Why Is Axsome (AXSM) Up 18.6% Since Last Earnings Report?

by Zacks Equity Research

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.